Trials / Completed
CompletedNCT05376241
Promoting Informed Choice for Breast Cancer Screening
Understanding Affective Processing of Scientific Evidence to Promote Informed Choice for Breast Cancer Screening
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 637 (actual)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- Female
- Age
- 39 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
Identify the prevalence and predictors of reactance, self-exemption, disbelief, source derogation in reaction to evidence about mammography benefits and harms, and consequences for decision-making and trust.
Detailed description
In this study, the goal is to identify the prevalence and predictors of reactance, self-exemption, disbelief, and source derogation in reaction to evidence about mammography benefits and harms, and consequences for decision-making and trust. Research has not yet systematically identified the proportion of women who respond negatively (vs. positively) to evidence about the benefits and harms of mammography screening, or attempted to explain these responses by examining theory-driven predictors. The Investigator will develop and conduct a probability-based nationally representative survey in which mammography evidence is communicated using current best practices in risk communication. The Investigators will identify theory-driven predictors of negative and positive responses to that evidence, and identify consequences of these responses for screening decision-making and trust.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Decision aid | Mammography screening decision aid for women in their 40s with information about screening guidelines, breast cancer mortality reduction, false positives, overdiagnosis, and a personal breast cancer risk estimate. |
Timeline
- Start date
- 2022-01-03
- Primary completion
- 2022-05-07
- Completion
- 2022-05-07
- First posted
- 2022-05-17
- Last updated
- 2026-03-27
- Results posted
- 2025-10-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05376241. Inclusion in this directory is not an endorsement.